PRO-AH-001

About ProdIgY Biotech

ProdIgY Biotech is developing first-in-class, orally administered IgY antibody therapies that target the gut-liver axis to treat serious liver diseases, starting with alcohol-associated hepatitis (AH). Its lead candidate, PRO-AH-001, is designed to selectively neutralize the bacterial toxin cytolysin and its producer, addressing a root cause of disease progression with a non-systemic mechanism. Founded in 2018 and based in San Diego, the company is privately held and pre-revenue, with a preclinical pipeline that also includes programs for Primary Sclerosing Cholangitis (PSC) and Metabolic Dysfunction-Associated Steatohepatitis (MASH). The technology is supported by peer-reviewed research, including a 2023 cover publication in Hepatology.

Therapeutic Areas

Other Alcohol-Associated Hepatitis (AH) Drugs